160 related articles for article (PubMed ID: 24380871)
1. In vivo monitoring of sorafenib therapy effects on experimental prostate carcinomas using dynamic contrast-enhanced MRI and macromolecular contrast media.
Cyran CC; Schwarz B; Paprottka PM; Sourbron S; von Einem JC; Dietrich O; Hinkel R; Clevert DA; Bruns CJ; Reiser MF; Nikolaou K; Wintersperger BJ
Cancer Imaging; 2013 Dec; 13(4):557-66. PubMed ID: 24380871
[TBL] [Abstract][Full Text] [Related]
2. Dynamic contrast-enhanced computed tomography imaging biomarkers correlated with immunohistochemistry for monitoring the effects of sorafenib on experimental prostate carcinomas.
Cyran CC; von Einem JC; Paprottka PM; Schwarz B; Ingrisch M; Dietrich O; Hinkel R; Bruns CJ; Clevert DA; Eschbach R; Reiser MF; Wintersperger BJ; Nikolaou K
Invest Radiol; 2012 Jan; 47(1):49-57. PubMed ID: 21934514
[TBL] [Abstract][Full Text] [Related]
3. Perfusion MRI for monitoring the effect of sorafenib on experimental prostate carcinoma: a validation study.
Cyran CC; Paprottka PM; Schwarz B; Sourbron S; Ingrisch M; von Einem J; Pietsch H; Dietrich O; Hinkel R; Bruns CJ; Reiser MF; Wintersperger BJ; Nikolaou K
AJR Am J Roentgenol; 2012 Feb; 198(2):384-91. PubMed ID: 22268182
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of a novel macromolecular cascade-polymer contrast medium for dynamic contrast-enhanced MRI monitoring of antiangiogenic bevacizumab therapy in a human melanoma model.
Cyran CC; Fu Y; Rogut V; Chaopathomkul B; Wendland MF; Shames DM; Brasch RC
Acad Radiol; 2013 Oct; 20(10):1256-63. PubMed ID: 24029057
[TBL] [Abstract][Full Text] [Related]
5. Dynamic Contrast-Enhanced Magnetic Resonance Imaging as Imaging Biomarker for Vascular Normalization Effect of Infigratinib in High-FGFR-Expressing Hepatocellular Carcinoma Xenografts.
Tran A; Koh TS; Prawira A; Ho RZW; Le TBU; Vu TC; Hartano S; Teo XQ; Chen WC; Lee P; Thng CH; Huynh H
Mol Imaging Biol; 2021 Feb; 23(1):70-83. PubMed ID: 32909245
[TBL] [Abstract][Full Text] [Related]
6. DCE-MRI biomarkers for monitoring an anti-angiogenic triple combination therapy in experimental hypopharynx carcinoma xenografts with immunohistochemical validation.
Sterzik A; Paprottka PM; Zengel P; Hirner H; Roßpunt S; Eschbach R; Moser M; Havla L; Ingrisch M; Mack B; Reiser MF; Nikolaou K; Cyran CC
Acta Radiol; 2015 Mar; 56(3):294-303. PubMed ID: 24609871
[TBL] [Abstract][Full Text] [Related]
7. Monitoring anti-angiogenic therapy in colorectal cancer murine model using dynamic contrast-enhanced MRI: comparing pixel-by-pixel with region of interest analysis.
Haney CR; Fan X; Markiewicz E; Mustafi D; Karczmar GS; Stadler WM
Technol Cancer Res Treat; 2013 Feb; 12(1):71-8. PubMed ID: 22905809
[TBL] [Abstract][Full Text] [Related]
8. Characterization of tumor angiogenesis with dynamic contrast-enhanced MRI and biodegradable macromolecular contrast agents in mice.
Feng Y; Jeong EK; Mohs AM; Emerson L; Lu ZR
Magn Reson Med; 2008 Dec; 60(6):1347-52. PubMed ID: 19025902
[TBL] [Abstract][Full Text] [Related]
9. Contrast-Enhanced Ultrasound with VEGFR2-Targeted Microbubbles for Monitoring Regorafenib Therapy Effects in Experimental Colorectal Adenocarcinomas in Rats with DCE-MRI and Immunohistochemical Validation.
Eschbach RS; Clevert DA; Hirner-Eppeneder H; Ingrisch M; Moser M; Schuster J; Tadros D; Schneider M; Kazmierczak PM; Reiser M; Cyran CC
PLoS One; 2017; 12(1):e0169323. PubMed ID: 28060884
[TBL] [Abstract][Full Text] [Related]
10. Assessment of early therapeutic response to sorafenib in renal cell carcinoma xenografts by dynamic contrast-enhanced and diffusion-weighted MR imaging.
Jeon TY; Kim CK; Kim JH; Im GH; Park BK; Lee JH
Br J Radiol; 2015 Sep; 88(1053):20150163. PubMed ID: 26133222
[TBL] [Abstract][Full Text] [Related]
11. Magnetic resonance imaging assays for dimethyl sulfoxide effect on cancer vasculature.
Cyran CC; Sennino B; Chaopathomkul B; Fu Y; Rogut V; Shames DM; Wendland MF; McDonald DM; Brasch RC
Invest Radiol; 2008 May; 43(5):298-305. PubMed ID: 18424950
[TBL] [Abstract][Full Text] [Related]
12. Pilot study of DCE-MRI to predict progression-free survival with sorafenib therapy in renal cell carcinoma.
Flaherty KT; Rosen MA; Heitjan DF; Gallagher ML; Schwartz B; Schnall MD; O'Dwyer PJ
Cancer Biol Ther; 2008 Apr; 7(4):496-501. PubMed ID: 18219225
[TBL] [Abstract][Full Text] [Related]
13. Correlation of perfusion MRI and 18F-FDG PET imaging biomarkers for monitoring regorafenib therapy in experimental colon carcinomas with immunohistochemical validation.
Eschbach RS; Fendler WP; Kazmierczak PM; Hacker M; Rominger A; Carlsen J; Hirner-Eppeneder H; Schuster J; Moser M; Havla L; Schneider MJ; Ingrisch M; Spaeth L; Reiser MF; Nikolaou K; Cyran CC
PLoS One; 2015; 10(2):e0115543. PubMed ID: 25668193
[TBL] [Abstract][Full Text] [Related]
14. Early antiangiogenic activity of SU11248 evaluated in vivo by dynamic contrast-enhanced magnetic resonance imaging in an experimental model of colon carcinoma.
Marzola P; Degrassi A; Calderan L; Farace P; Nicolato E; Crescimanno C; Sandri M; Giusti A; Pesenti E; Terron A; Sbarbati A; Osculati F
Clin Cancer Res; 2005 Aug; 11(16):5827-32. PubMed ID: 16115922
[TBL] [Abstract][Full Text] [Related]
15. Decrease in tumor apparent permeability-surface area product to a MRI macromolecular contrast medium following angiogenesis inhibition with correlations to cytotoxic drug accumulation.
Daldrup-Link HE; Okuhata Y; Wolfe A; Srivastav S; Øie S; Ferrara N; Cohen RL; Shames DM; Brasch RC
Microcirculation; 2004; 11(5):387-96. PubMed ID: 15280064
[TBL] [Abstract][Full Text] [Related]
16. Sorafenib (BAY 43-9006) inhibits tumor growth and vascularization and induces tumor apoptosis and hypoxia in RCC xenograft models.
Chang YS; Adnane J; Trail PA; Levy J; Henderson A; Xue D; Bortolon E; Ichetovkin M; Chen C; McNabola A; Wilkie D; Carter CA; Taylor IC; Lynch M; Wilhelm S
Cancer Chemother Pharmacol; 2007 Apr; 59(5):561-74. PubMed ID: 17160391
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of KRAS mutations, angiogenic biomarkers, and DCE-MRI in patients with advanced non-small-cell lung cancer receiving sorafenib.
Kelly RJ; Rajan A; Force J; Lopez-Chavez A; Keen C; Cao L; Yu Y; Choyke P; Turkbey B; Raffeld M; Xi L; Steinberg SM; Wright JJ; Kummar S; Gutierrez M; Giaccone G
Clin Cancer Res; 2011 Mar; 17(5):1190-9. PubMed ID: 21224376
[TBL] [Abstract][Full Text] [Related]
18. Dynamic contrast-enhanced magnetic resonance imaging pharmacodynamic biomarker study of sorafenib in metastatic renal carcinoma.
Hahn OM; Yang C; Medved M; Karczmar G; Kistner E; Karrison T; Manchen E; Mitchell M; Ratain MJ; Stadler WM
J Clin Oncol; 2008 Oct; 26(28):4572-8. PubMed ID: 18824708
[TBL] [Abstract][Full Text] [Related]
19. Comparison of dynamic contrast-enhanced magnetic resonance imaging and contrast-enhanced ultrasound for evaluation of the effects of sorafenib in a rat model of hepatocellular carcinoma.
Muñoz NM; Minhaj AA; Maldonado KL; Kingsley CV; Cortes AC; Taghavi H; Polak U; Mitchell JM; Ensor JE; Bankson JA; Rashid A; Avritscher R
Magn Reson Imaging; 2019 Apr; 57():156-164. PubMed ID: 30465870
[TBL] [Abstract][Full Text] [Related]
20. MRI assessment of early tumor response in metastatic renal cell carcinoma patients treated with sorafenib.
Kang HC; Tan KS; Keefe SM; Heitjan DF; Siegelman ES; Flaherty KT; O'Dwyer PJ; Rosen MA
AJR Am J Roentgenol; 2013 Jan; 200(1):120-6. PubMed ID: 23255750
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
